Yahoo
NasdaqGS - Nasdaq Real Time Price USD

Milestone Pharmaceuticals Inc. (MIST)

1.0950 -0.1750 (-13.78%)
As of 9:52:36 AM EDT. Market Open.
Trade MIST on Coinbase
MIST Q2 2026 earnings call
Replay the call for the latest insights.
Chart Range Bar
Loading chart for MIST

News headlines Milestone Pharmaceuticals (MIST) reported a Q2 adjusted loss of $0.21 per share, missing estimates and driving shares down 12.6%. Revenue of $0.56 millionalso lagged behind expectations, raising concerns about its financial outlook and future growth potential.

Milestone Pharmaceuticals (MIST) reported a Q2 adjusted loss of $0.21 per share, missing estimates and driving shares down 12.6%. Revenue of $0.56 millionalso lagged behind expectations, raising concerns about its financial outlook and future growth potential.

Updated 15m ago · Powered by Yahoo Scout
  • Previous Close 1.2700
  • Open 1.0420
  • Bid 1.0000 x 200
  • Ask 1.1200 x 100
  • Day's Range 1.0400 - 1.1250
  • 52 Week Range 1.0000 - 3.0600
  • Volume 2,415,468
  • Avg. Volume 1,377,924
  • Market Cap (intraday) 136.325M
  • Beta (5Y Monthly) 0.98
  • PE Ratio (TTM) --
  • EPS (TTM) -0.6400
  • Earnings Date Aug 12, 2026
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 6.33

Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines in the United States and Canada. It offers CARDAMYST (etripamil) nasal spray, a prescription medication for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults. The company is also developing etripamil for the indication of atrial fibrillation with rapid ventricular rate (AFib-RVR). It has a license and collaboration agreement with Corxel Pharmaceuticals to develop and commercialize etripamil. Milestone Pharmaceuticals Inc.was incorporated in 2003 and is headquartered in Montreal, Canada.

www.milestonepharma.com

38

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Performance Overview

Trailing total returns as of 8/12/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

MIST
45.79%
S&P 500 (^GSPC)
13.22%

1-Year Return

MIST
34.04%
S&P 500 (^GSPC)
20.24%

3-Year Return

MIST
65.46%
S&P 500 (^GSPC)
73.62%

5-Year Return

MIST
79.53%
S&P 500 (^GSPC)
73.74%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q1 FY26
Revenue 238k
Earnings -26.07M

Q3

FY25

Q4

FY25

Q1

FY26

-25M
-20M
-15M
-10M
-5M
0

Analyst Insights

View More

Top Analyst

HC Wainwright & Co.
46/100
Latest Rating
Buy

Analyst Price Targets

2.00
6.33 Average
1.0950 Current
8.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 5/14/2026
Analyst Wells Fargo
Rating Action Maintains
Rating Overweight
Price Action Lowers
Price Target 8 -> 7

Statistics

View More

Valuation Measures

Annual
As of 8/10/2026
  • Market Cap

    156.24M

  • Enterprise Value

    31.25M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    70.55

  • Price/Book (mrq)

    4.35

  • Enterprise Value/Revenue

    17.86

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -31.92%

  • Return on Equity (ttm)

    -456.88%

  • Revenue (ttm)

    1.78M

  • Net Income Avi to Common (ttm)

    -68.36M

  • Diluted EPS (ttm)

    -0.6400

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    184.22M

  • Total Debt/Equity (mrq)

    380.95%

  • Levered Free Cash Flow (ttm)

    -32.63M

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Company Insights

Fair Value

1.0950 Current

Dividend Score

0 Low
Sector Avg.
100 High

Hiring Score

0 Low
Sector Avg.
100 High

Insider Sentiment Score

0 Low
Sector Avg.
100 High

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: